Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan in solid tumors
NCT05119907Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2021
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in Esophageal Squamous Cell Carcinoma (ESCC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, Cervical Cancer (CC), biliary tract cancer (BTC), sponsored by Gilead Sciences. Started Oct 2021; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)gastric adenocarcinomagastroesophageal junction adenocarcinomaCervical Cancer (CC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05119907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05119907.